We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
Read MoreHide Full Article
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%. Elsewhere, the Dow gained 0.24%, while the tech-heavy Nasdaq added 0.36%.
Heading into today, shares of the biotechnology company had gained 12.95% over the past month, outpacing the Medical sector's loss of 1.19% and the S&P 500's gain of 5.98%.
Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.27, indicating a 46% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $20.73 million, indicating a 40.65% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.93 per share and a revenue of $90.52 million, demonstrating changes of +35.42% and +21.21%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Recursion Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Recursion Pharmaceuticals presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Recursion Pharmaceuticals (RXRX) Stock Drops Despite Market Gains: Important Facts to Note
In the latest trading session, Recursion Pharmaceuticals (RXRX - Free Report) closed at $3.60, marking a -4% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.26%. Elsewhere, the Dow gained 0.24%, while the tech-heavy Nasdaq added 0.36%.
Heading into today, shares of the biotechnology company had gained 12.95% over the past month, outpacing the Medical sector's loss of 1.19% and the S&P 500's gain of 5.98%.
Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company is predicted to post an EPS of -$0.27, indicating a 46% growth compared to the equivalent quarter last year. Meanwhile, the latest consensus estimate predicts the revenue to be $20.73 million, indicating a 40.65% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of -$0.93 per share and a revenue of $90.52 million, demonstrating changes of +35.42% and +21.21%, respectively, from the preceding year.
Investors should also note any recent changes to analyst estimates for Recursion Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Recursion Pharmaceuticals presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.